The Latest Cardiac and Vascular News
HOUSTON, Aug. 16, 2022 /PRNewswire/ — Millar, Inc., a medical device manufacturer and OEM solutions partner, is pleased to announce that they have received approval from the Therapeutic Goods Administration (TGA) in Australia for their Mikro-Cath™ Pressure Catheter. The Mikro-Cath™ is a single–use pressure catheter intended to be used for medical research and diagnostic purposes. The […]
To provide a full spectrum of innovative solutions, the partnership aims to empower better heart care and build efficiency across the care pathway journey of the patient Unlocking the potential of interventional cardiology will be a step forward in delivering precision health BENGALURU, India, Aug. 16, 2022 /PRNewswire/ — GE Healthcare, a leading global […]
• Topline data expected mid-2023 • EXPLORER-CN trial, together with PK study conducted in healthy Chinese volunteers, expected to support registration of mavacamten in China SHANGHAI, China and PRINCETON, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in […]
Oxford University mathematics program paired students & faculty with Vironix technologists to develop and validate algorithms for synthetic patient data generation and detection of Congestive Heart Failure decompensation. AUSTIN, Texas, Aug. 9, 2022 /PRNewswire/ — Digital Health Company, Vironix Health, has teamed up with the Mathematical Modelling and Scientific Computing MSc, based within […]
The Bodyport Cardiac Scale is available to monitor heart function and fluid status in a single step at home SAN FRANCISCO–(BUSINESS WIRE)–Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug […]
Modern Heart and Vascular Institute is proud to offer an intensive cardiac rehabilitation program designed to help patients get back to their normal lives after being diagnosed with cardiovascular disease. HUMBLE, Texas, Aug. 08, 2022 (GLOBE NEWSWIRE) — Modern Heart and Vascular is now offering intensive cardiac rehabilitation for patients […]
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value < 0.0001) decline on a placebo-adjusted basis, at 2 mg dose Independent Data Review Committee determined that the trial met pre-specified statistical criteria of overwhelming efficacy […]
Aligned with CHOP and AHA’s shared mission to improve cardiac care, grant supports research aiming to discover new hormones secreted from the heart PHILADELPHIA, Aug. 4, 2022 /PRNewswire/ — Children’s Hospital of Philadelphia (CHOP) has received a $400,000 grant from the American Heart Association (AHA) to help study heart-secreted hormones. The funding, which will be disbursed in yearly increments […]
LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it has signed a collaboration agreement with the German Heart Centre Berlin (DHZB), a leading medical research institute specializing in cardiovascular disease. This agreement focuses on the development of a suite of innovative solutions that will facilitate the diagnosis and treatment […]
– Patisiran Met the Primary Endpoint with a Statistically Significant Improvement in 6-Minute Walk Test Compared to Placebo at 12 Months – – Patisiran Also Met the First Secondary Endpoint with a Statistically Significant Improvement in Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire, Compared to Placebo […]
